Biocon Limited has informed the Exchange regarding a press release dated August 05, 2026, titled "Biocon Q1FY27 Total Income at Rs 4,391 Cr, Up 9%; EBITDA at Rs 902 Cr; Net Profit at Rs 141 Cr; Biopharma Revenue Up 17%".
Biocon Limited Press Release Aug 05 2026
Filed with NSE · · 10 pages · English
Release
In the deck
Earlier from Biocon
- Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg
- Biocon Limited Press Release Aug 03 2026
- Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili, a Biosimilar to Eylea
- Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)
- Biocon Limited Press Release Jul 09 2026
Later from Biocon
- Biocon Launches Aflibercept Biosimilar In The United States
- Biocon Announces Supplemental U.S. FDA Approval For Prefilled Autoinjector For YESINTEK
- Biocon Limited Press Release Sep 08 2026
- Biocon Limited Press Release Sep 21 2026
- Biocon's Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon